ATG13 and neoplasm: In contrast, ULK1 inhibitor SBI-0206965 [55] and/or ATG13-KO alone were not strong enough to inhibit tumor growth as efficiently as DKO (Fig 7H and 7I), indicating that targeting ULK1 and ATG13 together might be a potential anticancer strategy.